Recent papers/presentations:

Flower K, Li L, Chen C, Baggott MJ, Galloway GP, Mendelson J. (2010) Efficacy, safety, and ethics of cosmetic neurology far from settled. Clinical Pharmacology and Therapeutics (2010) [88 4], 461-463. doi:10.1038/clpt.2010.194.

Salo R, Flower K, Kielstein A, Leamon MH , Nordahl TE, Galloway GP. (2011) Psychiatric co-morbidity in methamphetamine dependence. Psychiatry Research (2011) Apr 30;186(2-3):356-61. Epub 2010 Nov 4.

Mendelson J, Baggott MJ, Flower K, Galloway G. Developing biomarkers for methamphetamine addiction. Current Neuropharmacology. 9. 1 (Mar 2011): 100-103.

Galloway GP, Buscemi R, Coyle JR, Flower K, Siegrist JD, Fiske LA, Li L, Baggott MJ, Polcin D, Chen CYA, Mendelson JE. (2011) A randomized, placebo-controlled trial of sustained release dextroamphetamine for methamphetamine addiction. Clinical Pharmacology and Therapeutics. (2011) Feb;89(2):276-82. Epub 2010 Dec 22.

Flower K, Post A, Mendelson JE, Sussman J, Tangherlini N, Pletcher M. (2010) Validation of triage criteria for deciding which apparently inebriated persons require emergency department care. Emergency Medicine Journal. doi:10.1136/emj.2009.089763.

Mendelson JE, Coyle JR, Lopez JC, Baggott MJ, Flower K, Everhart ET, Munro TA, Galloway GP, Cohen BM. (2010) Lack of effect of sublingual Salvinorin A, a naturally occurring kappa opioid, in humans: a placebo controlled trial. Psychopharmacology. (2011) Apr;214(4):933-9. Epub 2010 Dec 8.

Galloway GP, Coyle JR, Guillen JE, Flower K, Mendelson J. A simple, novel method for assessing medication adherence: pill photographs taken with cellular telephones. (2011) Journal of Addiction Medicine. (2011) doi: 10.1097/ADM.0b013e3181fcb5fd.

Leamon ML, Flower K, Salo R, Nordahl TE, Galloway GP (2010). Methamphetamine and paranoia: the Methamphetamine Experience Questionnaire. American Journal on Addictions. 2010 Mar;19(2):155-68.

Mendelson JE, Tolliver BK, Delucchi KL, Baggott MJ, Flower K, Harris CW Galloway GP, Berger P (2009). Capsaicin, an active ingredient in pepper sprays, increases the lethality of cocaine. Forensic Toxicology, 16(4):319-322.

Flower, K. A pilot trial of modafinil for methamphetamine dependence. National Institutes on Drug Abuse, Medications Center of Excellence (P50) Meeting Presentation, March 31, 2009, San Francisco, CA.

Mendelson JE, Flower K, Pletcher MJ, Galloway GP (2008). Addiction to prescription opioids: characteristics of the emerging epidemic and treatment with buprenorphine. Experimental and Clinical Psychopharmacology, 16(5):435-441.

Flower K, Mendelson JE, Galloway GP (2008). GHB. In Principles of Addiction Medicine, 4th Edition, pp. 461-464.

Grant Support

R01 DA027161-01 NIDA, 08/2009 - 10/2010 Principal Investigator: A pilot trial of sustained release naltrexone for methamphetamine addiction - role of the A118G single nucleotide polymorphism

HHSN271200788631C NIDA, 10/2007 - 10/2010 Co-Investigator: Phase II NIDA clinical trial of bupropion for methamphetamine dependence

R01 DA023567 NIDA, 2008 - 10/2010 Co-Investigator: A dose ranging study of modafinil for methamphetamine dependence

R01 DA016776 NIDA, 09/04 - 10/2010 Co-Investigator: Clinical pharmacology of 3,4-methylenedioxy amphetamine

Harvard University 07/2007 - 07/2008 Co-Investigator: A double blind, placebo-controlled, ascending dose pharmacodynamic and tolerability study of 100 to 4000 ug of sublingual Salvinorin A

R01 DA017716 NIDA, 07/2005 - 04/2009 Co-Investigator: MDMA dependence and discontinuation syndrome

P50 DA018179 NIDA, 09/29/2004 - 10/2010 Co-Investigator: Methamphetamine Pharmacotherapy Development Center (P50 Center)

CPP-01004 Health Decisions Adaptive, 09/2007 - 03/2009 Co-Investigator: Vigabatrin for treatment of cocaine dependence: a phase II study

CPP-02001 Health Decisions Adaptive, 08/2008 - 12/2009 Co-Investigator: Vigabatrin for treatment of methamphetamine dependence: a phase II study